ProMIS Neurosciences, Inc. (PMN) Amount of Cash per Share

Corporate emblem and logo of ProMIS Neurosciences Inc. (PMN)

The lack of recurring revenue makes the stability of ProMIS Neurosciences (PMN) dependent on the outcome of drug trials. Current cash per share confirms liquidity, with the metric holding around 4.87. The development of selective amyloid antibodies to combat Alzheimer's disease, as well as the potential for acquisition by pharmaceutical market behemoths following successful clinical phases, mitigates these risks.

PMN promisneurosciences.com: Cash Funds per Share in the range 06/27/2023 - 11/20/2026

Analytical breakdowns for ProMIS Neurosciences

- stock price and consensus target price:
- market capitalization details:
- cash position and cash flow details:
General company analysis:ProMIS Neurosciences Inc. - PMN
Manufactured product of promisneurosciences.com

Geopolitical instability and sanctions are complicating the funding of neurological research at ProMIS Neurosciences (PMN). The dynamics of free cash flow per share allow for a real-time assessment of the company's current liquidity against these risks. The 4.87 metric is calculated by dividing the total amount of highly liquid assets by the total number of shares. This metric determines the balance sheet's margin of safety for covering operating expenses. An increase in this value confirms financial autonomy, reducing the business's reliance on external borrowing.